Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel Followed by Radical Prostatectomy in High Risk Localized Prostate Cancer
NCT00005096Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 1999
- Primary completion
- Jun 2002
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel in prostate cancer (PCa), sponsored by Dana-Farber Cancer Institute. Primary endpoint: Pathologic Complete Response Rate at 6 Months. Started Dec 1999; status: completed.
02
Drugs
docetaxel
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT00005096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00005096.